{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:11:26Z","timestamp":1778490686892,"version":"3.51.4"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The epidemic of the novel coronavirus disease (COVID-19) that started in 2019 has evoked an urgent demand for finding new potential therapeutic agents. In this study, we performed a molecular docking of anti-HIV drugs to refine HIV protease inhibitors and nucleotide analogues to target COVID-19. The evaluation was based on docking scores calculated by AutoDock Vina and top binding poses were analyzed. Our results suggested that lopinavir, darunavir, atazanavir, remdesivir, and tipranavir have the best binding affinity for the 3-chymotrypsin-like protease of COVID-19. The comparison of the binding sites of three drugs, namely, darunavir, atazanavir and remdesivir, showed an overlap region of the protein pocket. Our study showed a strong affinity between lopinavir, darunavir, atazanavir, tipranavir and COVID-19 protease. However, their efficacy should be confirmed by\n                    <jats:italic>in vitro<\/jats:italic>\n                    studies since there are concerns related to interference with their active sites.\n                  <\/jats:p>","DOI":"10.2478\/acph-2022-0010","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T17:47:27Z","timestamp":1630432047000},"page":"1-8","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of COVID-19 protease and HIV inhibitors interactions"],"prefix":"10.2478","volume":"72","author":[{"given":"Linh","family":"Tran","sequence":"first","affiliation":[{"name":"Institute of Fundamental and Applied Sciences Duy Tan University , Ho Chi Minh City 700000 Vietnam"},{"name":"Faculty of Natural Sciences , Duy Tan University Da Nang City, 550000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao Ngoc Hien","family":"Tam","sequence":"additional","affiliation":[{"name":"Asia Shine Trading & Service Co. Ltd ., Ho Chi Minh City, 700000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Elhadad","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Medical Research Institute , Alexandria University , Alexandria , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Minh","family":"Hien","sequence":"additional","affiliation":[{"name":"School of Medicine , Vietnam National University Ho Chi Minh City, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Tien","family":"Huy","sequence":"additional","affiliation":[{"name":"Department of Clinical Product Development, Institute of Tropical Medicine, School of Tropical Medicine and Global Health , Nagasaki University Nagasaki 852-8523 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"2026051108211886746_j_acph-2022-0010_ref_001","doi-asserted-by":"crossref","unstructured":"1. F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E. C. Holmes and Y.-Z. Zhang, A new coronavirus associated with human respiratory disease in China, Nature 579 (2020) 265\u2013269; https:\/\/doi.org\/10.1038\/s41586-020-2008-310.1038\/s41586-020-2008-3709494332015508","DOI":"10.1038\/s41586-020-2008-3"},{"key":"2026051108211886746_j_acph-2022-0010_ref_002","doi-asserted-by":"crossref","unstructured":"2. J. Xu, S. Zhao, T. Teng, A. E. Abdalla, W. Zhu, L. Xie, Y. Wang and X. Guo, Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV, Viruses 12 (2020) Article ID 244; https:\/\/doi.org\/10.3390\/v1202024410.3390\/v12020244707719132098422","DOI":"10.3390\/v12020244"},{"key":"2026051108211886746_j_acph-2022-0010_ref_003","doi-asserted-by":"crossref","unstructured":"3. Z. Wang, X. Chen, Y. Lu, F. Chen and W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, Biosci. Trends 14 (2020) 64\u201368; https:\/\/doi.org\/10.5582\/bst.2020.0103010.5582\/bst.2020.0103032037389","DOI":"10.5582\/bst.2020.01030"},{"key":"2026051108211886746_j_acph-2022-0010_ref_004","doi-asserted-by":"crossref","unstructured":"4. J. Lim, S. Jeon, H. Y. Shin, M. J. Kim, Y. M. Seong, W. J. Lee, K. W. Choe, Y. M. Kang, B. Lee and S. J. Park, Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, J. Korean Med. Sci. 35 (2020) e79; https:\/\/doi.org\/10.3346\/jkms.2020.35.e7910.3346\/jkms.2020.35.e79702591032056407","DOI":"10.3346\/jkms.2020.35.e79"},{"key":"2026051108211886746_j_acph-2022-0010_ref_005","doi-asserted-by":"crossref","unstructured":"5. C. M. Chu, V. C. Cheng, I. F. Hung, M. M. Wong, K. H. Chan, K. S. Chan, R. Y. Kao, L. L. Poon, C. L. Wong, Y. Guan, J. S. Peiris and K. Y. Yuen, Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax 59 (2004) 252\u2013256; https:\/\/doi.org\/10.1136\/thorax.2003.01265810.1136\/thorax.2003.012658174698014985565","DOI":"10.1136\/thorax.2003.012658"},{"key":"2026051108211886746_j_acph-2022-0010_ref_006","doi-asserted-by":"crossref","unstructured":"6. S. J. Hurwitz and R. F. Schinazi, Practical considerations for developing nucleoside reverse transcriptase inhibitors, Drug Discov. Today Technol. 9 (2012) e183\u2013e193; https:\/\/doi.org\/10.1016\/j.ddtec.2012.09.00310.1016\/j.ddtec.2012.09.003361202523554824","DOI":"10.1016\/j.ddtec.2012.09.003"},{"key":"2026051108211886746_j_acph-2022-0010_ref_007","doi-asserted-by":"crossref","unstructured":"7. N. Atatreh, S. Hasan, B. R. Ali and M. A. Ghattas, Computer-aided approaches reveal trihydroxychroman and pyrazolone derivatives as potential inhibitors of SARS-CoV-2 virus main protease, Acta Pharm. 71 (2021) 325\u2013333; https:\/\/doi.org\/10.2478\/acph-2021-004010.2478\/acph-2021-0040","DOI":"10.2478\/acph-2021-0040"},{"key":"2026051108211886746_j_acph-2022-0010_ref_008","doi-asserted-by":"crossref","unstructured":"8. Z. Lv, Y. Chu and Y. Wang, HIV protease inhibitors: a review of molecular selectivity and toxicity, HIV\/AIDS (Auckland) 7 (2015) 95\u2013104; https:\/\/doi.org\/10.2147\/HIV.S7995610.2147\/HIV.S79956439658225897264","DOI":"10.2147\/HIV.S79956"},{"key":"2026051108211886746_j_acph-2022-0010_ref_009","doi-asserted-by":"crossref","unstructured":"9. Y. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang, Z. Zhou, L. Han, K. Karapetyan, S. Dracheva, B. A. Shoemaker, E. Bolton, A. Gindulyte and S. H. Bryant, PubChem\u2019s BioAssay Database, Nucleic Acids Res. 40 (2012) D400-D412; https:\/\/doi.org\/10.1093\/nar\/gkr113210.1093\/nar\/gkr1132324505622140110","DOI":"10.1093\/nar\/gkr1132"},{"key":"2026051108211886746_j_acph-2022-0010_ref_010","doi-asserted-by":"crossref","unstructured":"10. N. M. O\u2019Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch and G. R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminform. 3 (2011) Article ID 33; https:\/\/doi.org\/10.1186\/1758-2946-3-3310.1186\/1758-2946-3-33319895021982300","DOI":"10.1186\/1758-2946-3-33"},{"key":"2026051108211886746_j_acph-2022-0010_ref_011","doi-asserted-by":"crossref","unstructured":"11. O. Trott and A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010) 455\u2013461; https:\/\/doi.org\/10.1002\/jcc.2133410.1002\/jcc.21334304164119499576","DOI":"10.1002\/jcc.21334"},{"key":"2026051108211886746_j_acph-2022-0010_ref_012","doi-asserted-by":"crossref","unstructured":"12. R. A. Laskowski and M. B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, J. Chem. Inf. Model. 51 (2011) 2778\u20132786; https:\/\/doi.org\/10.1021\/ci200227u10.1021\/ci200227u21919503","DOI":"10.1021\/ci200227u"},{"key":"2026051108211886746_j_acph-2022-0010_ref_013","doi-asserted-by":"crossref","unstructured":"13. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong and G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30 (2020) 269\u2013271; https:\/\/doi.org\/10.1038\/s41422-020-0282-010.1038\/s41422-020-0282-0705440832020029","DOI":"10.1038\/s41422-020-0282-0"},{"key":"2026051108211886746_j_acph-2022-0010_ref_014","doi-asserted-by":"crossref","unstructured":"14. S. Daoud, S. J. Alabed, L. A. Dahabiyeh, Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies, Acta Pharm. 71 (2021) 163\u2013174; https:\/\/doi.org\/10.2478\/acph-2021-001610.2478\/acph-2021-001633151166","DOI":"10.2478\/acph-2021-0016"},{"key":"2026051108211886746_j_acph-2022-0010_ref_015","doi-asserted-by":"crossref","unstructured":"15. T. P. Sheahan, A. C. Sims, S. R. Leist, A. Sch\u00e4fer, J. Won, A. J. Brown, S. A. Montgomery, A. Hogg, D. Babusis, M. O. Clarke, J. E. Spahn, L. Bauer, S. Sellers, D. Porter, J. Y. Feng, T. Cihlar, R. Jordan, M. R. Denison and R. S. Baric, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun. 11 (2020) Article ID 222; https:\/\/doi.org\/10.1038\/s41467-019-13940-610.1038\/s41467-019-13940-6695430231924756","DOI":"10.1038\/s41467-019-13940-6"},{"key":"2026051108211886746_j_acph-2022-0010_ref_016","doi-asserted-by":"crossref","unstructured":"16. A. H. de Wilde, D. Jochmans, C. C. Posthuma, J. C. Zevenhoven-Dobbe, S. van Nieuwkoop, T. M. Bestebroer, B. G. van den Hoogen, J. Neyts and E. J. Snijder, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother. 58 (2014) 4875\u20134884; https:\/\/doi.org\/10.1128\/AAC.03011-1410.1128\/AAC.03011-14413607124841269","DOI":"10.1128\/AAC.03011-14"},{"key":"2026051108211886746_j_acph-2022-0010_ref_017","unstructured":"17. E. C. Vatansever, K. S. Yang, K. Kratch, A. Drelich, C.-C. Cho, D. M. Mellot, S. Xu, C.-T. K. Tseng and W. R. Liu, Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19, bioRxiv preprint [Internet], posted May 23, 2020; https:\/\/doi.org\/10.1101\/2020.05.23.11223510.1101\/2020.05.23.112235726349832511370"},{"key":"2026051108211886746_j_acph-2022-0010_ref_018","doi-asserted-by":"crossref","unstructured":"18. B. R. Beck, B. Shin, Y. Choi, S. Park and K. Kang, Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Comput. Struct. Biotechnol. J. 18 (2020) 784\u2013790; https:\/\/doi.org\/10.1016\/j.csbj.2020.03.02510.1016\/j.csbj.2020.03.025711854132280433","DOI":"10.1016\/j.csbj.2020.03.025"},{"key":"2026051108211886746_j_acph-2022-0010_ref_019","doi-asserted-by":"crossref","unstructured":"19. M. A. M. Subbaiah, S. Mandlekar, S. Desikan, T. Ramar, L. Subramani, M. Annadurai, S. D. Desai, S. Sinha, S. M. Jenkins and M. R. Krystal, Design, synthesis, and pharmacokinetic evaluation of phosphate and amino acid ester prodrugs for improving the oral bioavailability of the HIV-1 protease inhibitor atazanavir, J. Med. Chem. 62 (2019) 3553\u20133574; https:\/\/doi.org\/10.1021\/acs.jmedchem.9b0000210.1021\/acs.jmedchem.9b0000230938524","DOI":"10.1021\/acs.jmedchem.9b00002"},{"key":"2026051108211886746_j_acph-2022-0010_ref_020","doi-asserted-by":"crossref","unstructured":"20. M. Rittweger and K. Arast\u00e9h, Clinical pharmacokinetics of darunavir, Clin. Pharmacokin. 46 (2007) 739\u2013756; https:\/\/doi.org\/10.2165\/00003088-200746090-0000210.2165\/00003088-200746090-0000217713972","DOI":"10.2165\/00003088-200746090-00002"},{"key":"2026051108211886746_j_acph-2022-0010_ref_021","doi-asserted-by":"crossref","unstructured":"21. M. Mahdi, J. A. M\u00f3ty\u00e1n, Z. I. Szojka, M. Golda, M. Miczi and J. T\u0151zs\u00e9r, Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2\u2019s main protease, Virol. J. 17 (2020) Article ID 190; https:\/\/doi.org\/10.1186\/s12985-020-01457-010.1186\/s12985-020-01457-0768964033243253","DOI":"10.1186\/s12985-020-01457-0"},{"key":"2026051108211886746_j_acph-2022-0010_ref_022","doi-asserted-by":"crossref","unstructured":"22. S. Jo, S. Kim and D. H. Shin, Inhibition of SARS-CoV 3CL protease by flavonoids, J. Enzyme Inhib. Med. Chem. 35 (2020) 145\u2013151; https:\/\/doi.org\/10.1080\/14756366.2019.169048010.1080\/14756366.2019.1690480688243431724441","DOI":"10.1080\/14756366.2019.1690480"},{"key":"2026051108211886746_j_acph-2022-0010_ref_023","doi-asserted-by":"crossref","unstructured":"23. L. Zhang, D. Lin, Y. Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J. Neyts, A. de Wilde, E. J. Snijder and H. Liu, \u03b1-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment, J. Med. Chem. 63 (2020) 4562\u20134578; https:\/\/doi.org\/10.1021\/acs.jmedchem.9b0182810.1021\/acs.jmedchem.9b01828709807032045235","DOI":"10.1021\/acs.jmedchem.9b01828"},{"key":"2026051108211886746_j_acph-2022-0010_ref_024","doi-asserted-by":"crossref","unstructured":"24. M. M. Ghahremanpour, J. Tirado-Rives, M. Deshmukh, J. A. Ippolito, C.-H. Zhang, I. Cabeza de Vaca, M.-E. Liosi, K. S. Anderson and W. L. Jorgensen, Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2, ACS Med. Chem. Lett. 11 (2020) 2526\u20132533; https:\/\/doi.org\/10.1021\/acsmedchemlett.0c0052110.1021\/acsmedchemlett.0c00521760532833324471","DOI":"10.1021\/acsmedchemlett.0c00521"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2022-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:48:44Z","timestamp":1778489324000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2022-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,30]]},"published-print":{"date-parts":[[2022,3,1]]}},"alternative-id":["10.2478\/acph-2022-0010"],"URL":"https:\/\/doi.org\/10.2478\/acph-2022-0010","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]}}}